FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2003204042> ?p ?o ?g. }

• W2003204042 endingPage "1104" @default.
• W2003204042 startingPage "1098" @default.
• W2003204042 abstract "Objective To examine the rates of long-term biochemical recurrence-free survival (BRFS) with respect to isotope in intermediate-risk prostate cancer treated with external beam radiotherapy (EBRT) and brachytherapy. Methods A total of 242 consecutive patients with intermediate-risk prostate cancer were treated with iodine-125 (125I) or palladium-103 (103Pd) implants after EBRT (range 45.0-50.4 Gy) from 1996 to 2002. Of the 242 patients, 119 (49.2%) were treated with 125I and 123 (50.8%) with 103Pd. Multivariate Cox regression analysis was used to analyze BRFS, defined according to the Phoenix definition (prostate-specific antigen nadir plus 2 ng/mL) with respect to Gleason score, stage, pretreatment prostate-specific antigen level, and source selection. Late genitourinary/gastrointestinal toxicities were assessed using the Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer scale. Results At a median follow-up of 10 years, the BRFS rate was 77.3%. A statistically significant difference was found in the 10-year BRFS rate between the 125I- and 103Pd-treated groups (82.7% and 70.6%, respectively; P = .001). The addition of hormonal therapy did not improve the 10-year BRFS rate (77.6%) compared with RT alone (77.1%; P = .22). However, a statistically significant difference in the BRFS rate was found with the addition of hormonal therapy to 103Pd, improving the 10-year BRFS rate for (73.8%) compared with 103Pd alone (69.1%; P = .008). On multivariate analysis, isotope type (103Pd vs 125I), pretreatment prostate-specific antigen level >10 ng/mL, and greater tumor stage increased the risk of recurrence by 2.6-fold (P = .007), 5.9-fold (P < .0001), and 1.7-fold (P = .14), respectively. Conclusion 125I renders a superior rate of BRFS compared with 103Pd when used with EBRT. Hormonal therapy does not provide additional benefit in patients with intermediate-risk prostate cancer treated with a combination of EBRT and brachytherapy, except for the addition of hormonal therapy to 103Pd. To examine the rates of long-term biochemical recurrence-free survival (BRFS) with respect to isotope in intermediate-risk prostate cancer treated with external beam radiotherapy (EBRT) and brachytherapy. A total of 242 consecutive patients with intermediate-risk prostate cancer were treated with iodine-125 (125I) or palladium-103 (103Pd) implants after EBRT (range 45.0-50.4 Gy) from 1996 to 2002. Of the 242 patients, 119 (49.2%) were treated with 125I and 123 (50.8%) with 103Pd. Multivariate Cox regression analysis was used to analyze BRFS, defined according to the Phoenix definition (prostate-specific antigen nadir plus 2 ng/mL) with respect to Gleason score, stage, pretreatment prostate-specific antigen level, and source selection. Late genitourinary/gastrointestinal toxicities were assessed using the Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer scale. At a median follow-up of 10 years, the BRFS rate was 77.3%. A statistically significant difference was found in the 10-year BRFS rate between the 125I- and 103Pd-treated groups (82.7% and 70.6%, respectively; P = .001). The addition of hormonal therapy did not improve the 10-year BRFS rate (77.6%) compared with RT alone (77.1%; P = .22). However, a statistically significant difference in the BRFS rate was found with the addition of hormonal therapy to 103Pd, improving the 10-year BRFS rate for (73.8%) compared with 103Pd alone (69.1%; P = .008). On multivariate analysis, isotope type (103Pd vs 125I), pretreatment prostate-specific antigen level >10 ng/mL, and greater tumor stage increased the risk of recurrence by 2.6-fold (P = .007), 5.9-fold (P < .0001), and 1.7-fold (P = .14), respectively. 125I renders a superior rate of BRFS compared with 103Pd when used with EBRT. Hormonal therapy does not provide additional benefit in patients with intermediate-risk prostate cancer treated with a combination of EBRT and brachytherapy, except for the addition of hormonal therapy to 103Pd." @default.
• W2003204042 created "2016-06-24" @default.
• W2003204042 creator A5004946413 @default.
• W2003204042 creator A5007428840 @default.
• W2003204042 creator A5024592292 @default.
• W2003204042 creator A5029893688 @default.
• W2003204042 creator A5033578637 @default.
• W2003204042 creator A5043314766 @default.
• W2003204042 creator A5043855883 @default.
• W2003204042 creator A5044633175 @default.
• W2003204042 creator A5059689655 @default.
• W2003204042 creator A5075567509 @default.
• W2003204042 date "2012-05-01" @default.
• W2003204042 modified "2023-09-23" @default.
• W2003204042 title "Role of Isotope Selection in Long-term Outcomes in Patients With Intermediate-risk Prostate Cancer Treated With a Combination of External Beam Radiotherapy and Low-dose-rate Interstitial Brachytherapy" @default.
• W2003204042 cites W1527435007 @default.
• W2003204042 cites W1985014098 @default.
• W2003204042 cites W1993558610 @default.
• W2003204042 cites W1997610387 @default.
• W2003204042 cites W2013638506 @default.
• W2003204042 cites W2014921832 @default.
• W2003204042 cites W2031877879 @default.
• W2003204042 cites W2037571122 @default.
• W2003204042 cites W2063556517 @default.
• W2003204042 cites W2071627324 @default.
• W2003204042 cites W2072653737 @default.
• W2003204042 cites W2075810750 @default.
• W2003204042 cites W2093867637 @default.
• W2003204042 cites W2103429819 @default.
• W2003204042 cites W2120328250 @default.
• W2003204042 cites W2122530789 @default.
• W2003204042 cites W2135257055 @default.
• W2003204042 cites W2135435808 @default.
• W2003204042 cites W2167842599 @default.
• W2003204042 cites W4238406133 @default.
• W2003204042 doi "https://doi.org/10.1016/j.urology.2012.01.043" @default.
• W2003204042 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3623292" @default.
• W2003204042 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22546388" @default.
• W2003204042 hasPublicationYear "2012" @default.
• W2003204042 type Work @default.
• W2003204042 sameAs 2003204042 @default.
• W2003204042 citedByCount "5" @default.
• W2003204042 countsByYear W20032040422013 @default.
• W2003204042 countsByYear W20032040422015 @default.
• W2003204042 countsByYear W20032040422016 @default.
• W2003204042 countsByYear W20032040422019 @default.
• W2003204042 countsByYear W20032040422020 @default.
• W2003204042 crossrefType "journal-article" @default.
• W2003204042 hasAuthorship W2003204042A5004946413 @default.
• W2003204042 hasAuthorship W2003204042A5007428840 @default.
• W2003204042 hasAuthorship W2003204042A5024592292 @default.
• W2003204042 hasAuthorship W2003204042A5029893688 @default.
• W2003204042 hasAuthorship W2003204042A5033578637 @default.
• W2003204042 hasAuthorship W2003204042A5043314766 @default.
• W2003204042 hasAuthorship W2003204042A5043855883 @default.
• W2003204042 hasAuthorship W2003204042A5044633175 @default.
• W2003204042 hasAuthorship W2003204042A5059689655 @default.
• W2003204042 hasAuthorship W2003204042A5075567509 @default.
• W2003204042 hasBestOaLocation W20032040422 @default.
• W2003204042 hasConcept C121608353 @default.
• W2003204042 hasConcept C126322002 @default.
• W2003204042 hasConcept C126894567 @default.
• W2003204042 hasConcept C143998085 @default.
• W2003204042 hasConcept C2775908122 @default.
• W2003204042 hasConcept C2776235491 @default.
• W2003204042 hasConcept C2777008409 @default.
• W2003204042 hasConcept C2777416452 @default.
• W2003204042 hasConcept C2778311097 @default.
• W2003204042 hasConcept C2779466945 @default.
• W2003204042 hasConcept C2780192828 @default.
• W2003204042 hasConcept C2781406297 @default.
• W2003204042 hasConcept C2989005 @default.
• W2003204042 hasConcept C509974204 @default.
• W2003204042 hasConcept C71924100 @default.
• W2003204042 hasConceptScore W2003204042C121608353 @default.
• W2003204042 hasConceptScore W2003204042C126322002 @default.
• W2003204042 hasConceptScore W2003204042C126894567 @default.
• W2003204042 hasConceptScore W2003204042C143998085 @default.
• W2003204042 hasConceptScore W2003204042C2775908122 @default.
• W2003204042 hasConceptScore W2003204042C2776235491 @default.
• W2003204042 hasConceptScore W2003204042C2777008409 @default.
• W2003204042 hasConceptScore W2003204042C2777416452 @default.
• W2003204042 hasConceptScore W2003204042C2778311097 @default.
• W2003204042 hasConceptScore W2003204042C2779466945 @default.
• W2003204042 hasConceptScore W2003204042C2780192828 @default.
• W2003204042 hasConceptScore W2003204042C2781406297 @default.
• W2003204042 hasConceptScore W2003204042C2989005 @default.
• W2003204042 hasConceptScore W2003204042C509974204 @default.
• W2003204042 hasConceptScore W2003204042C71924100 @default.
• W2003204042 hasIssue "5" @default.
• W2003204042 hasLocation W20032040421 @default.
• W2003204042 hasLocation W20032040422 @default.
• W2003204042 hasLocation W20032040423 @default.
• W2003204042 hasLocation W20032040424 @default.
• W2003204042 hasOpenAccess W2003204042 @default.
• W2003204042 hasPrimaryLocation W20032040421 @default.
• W2003204042 hasRelatedWork W1181291060 @default.
• W2003204042 hasRelatedWork W1979955543 @default.

• next